Try our beta test site
2 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) | DCDT2980S
Show Display Options
Rank Status Study
1 Completed A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Drug: DCDT2980S;   Drug: rituximab
2 Active, not recruiting A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Follicular, Diffuse Large B-Cell Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Pinatuzumab Vedotin;   Drug: Polatuzumab Vedotin;   Drug: Rituximab

Study has passed its completion date and status has not been verified in more than two years.